Pharma BD Deal Intelligence

Amgen Inc. / Micromet Inc.

2012 · Acquisition/Merger · $1.2B · Complete

Announcement Sentiment

Strongly positive

Amgen tender offer at $11/share cash for Micromet, valuing the company at approximately $1.16B. Acquisition delivered the BiTE bispecific antibody platform and lead asset blinatumomab in Phase 2 for relapsed/refractory ALL.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Accretive

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Jan 26, 2012
Closed Mar 08, 2012
Deal value $1.2B
Deal type Acquisition/Merger
Therapeutic area Acute lymphoblastic leukemia (ALL)
Indications Acute lymphoblastic leukemia (ALL)
Key assets Blinatumomab (BiTE)
Mechanism Bispecific T cell Engager (CD19/CD3)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals